News25/Ratings1
News · 26 weeks55-67%
2025-10-262026-04-19
Mix3890d
- SEC Filings16(42%)
- Insider12(32%)
- Other7(18%)
- Offering1(3%)
- Earnings1(3%)
- M&A1(3%)
Latest news
25 items- SECLifeward Ltd. filed SEC Form 8-K: Leadership Update8-K - Lifeward Ltd. (0001607962) (Filer)
- INSIDERSEC Form 4 filed by Sigsbee William Mark4 - Lifeward Ltd. (0001607962) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sigsbee William Mark3 - Lifeward Ltd. (0001607962) (Issuer)
- INSIDERSEC Form 4 filed by Rozenbaum Moshe H4 - Lifeward Ltd. (0001607962) (Issuer)
- INSIDERSEC Form 3 filed by new insider Rozenbaum Moshe H3 - Lifeward Ltd. (0001607962) (Issuer)
- SECSEC Form D filed by Lifeward Ltd.D - Lifeward Ltd. (0001607962) (Filer)
- SECLifeward Ltd. filed SEC Form 8-K: Other Events8-K - Lifeward Ltd. (0001607962) (Filer)
- INSIDERSEC Form 4 filed by Adar Almog4 - Lifeward Ltd. (0001607962) (Issuer)
- INSIDERSEC Form 4 filed by Grant William Mark4 - Lifeward Ltd. (0001607962) (Issuer)
- INSIDERSEC Form 4 filed by Reznick Yehuda4 - Lifeward Ltd. (0001607962) (Issuer)
- INSIDERSEC Form 4 filed by Kidron Nadav4 - Lifeward Ltd. (0001607962) (Issuer)
- INSIDERSEC Form 4 filed by Kidron Miriam4 - Lifeward Ltd. (0001607962) (Issuer)
- INSIDERSEC Form 3 filed by new insider Reznick Yehuda3 - Lifeward Ltd. (0001607962) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kidron Nadav3 - Lifeward Ltd. (0001607962) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kidron Miriam3 - Lifeward Ltd. (0001607962) (Issuer)
- SECLifeward Ltd. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits8-K - Lifeward Ltd. (0001607962) (Filer)
- PRLifeward Successfully Closes on Strategic Partnership with OramedHUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on the Company's previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). The transaction has positioned Lifeward as a diversified biomedical innovation company with an expected clear path to profitability. Lifeward acquired Oramed's clinical-stage Protein Oral Delivery (POD™) technology, adding exposure to a large, long-term biotech market opportunity
- SECLifeward Ltd. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Lifeward Ltd. (0001607962) (Filer)
- SECSEC Form 10-K filed by Lifeward Ltd.10-K - Lifeward Ltd. (0001607962) (Filer)
- SECLifeward Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Lifeward Ltd. (0001607962) (Filer)
- PRLifeward Reports Fourth Quarter and Full Year 2025 Financial ResultsAdvancing transformation into a diversified biomedical innovation company with a clear path to cash flow positive Oramed strategic transaction receives shareholder approval; Lifeward gains new oral protein delivery technology platform Lifeward already executing new strategy through acquisition of powered upper-body exoskeleton technology Lower operating expenses and cash usage reflect improved operational efficiency HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 18, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities,
- SECLifeward Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Lifeward Ltd. (0001607962) (Filer)
- PRLifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical CompanyPositions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that its shareholders approved the issuances of ordinary shares of the Company in connection with closing of the Co
- SECLifeward Ltd. filed SEC Form 8-K: Other Events8-K - Lifeward Ltd. (0001607962) (Filer)
- PRLifeward Regains Compliance with Nasdaq Minimum Bid Price RequirementHUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) ("Rule"). To regain compliance with the Rule, the Company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which the Company satisfied